- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Key HER2+ Patient Populations Evaluated in the DESTINY-Breast Program
Explore the latest advancements in HER2-positive breast cancer treatments, highlighting the promising results of DESTINY-Breast trials for improved patient outcomes.
EP: 1.Evolving Horizons in HER2-Positive Breast Cancer Care
EP: 2.Key HER2+ Patient Populations Evaluated in the DESTINY-Breast Program
EP: 3.Integrating Emerging DESTINY-Breast Data Into HER2+ Treatment Strategies
EP: 4.Interpreting Key Data From KATHERINE, HER2CLIMB-05, and PATINA
EP: 5.Defining Success in Metastatic Breast Cancer Trial Design
EP: 6.Personalized Selection of HER2+ Breast Cancer Therapies
EP: 7.Navigating ADC Use and Sequencing in HER2+ Breast Cancer
EP: 8.Balancing Efficacy and Safety in HER2+ Breast Cancer Trials
DESTINY-Breast05 and DESTINY-Breast11 examined distinct early breast cancer populations to better understand how novel HER2-targeted therapies may improve outcomes. DESTINY-Breast05 focused on patients with high-risk, residual disease after neoadjuvant therapy, while DESTINY-Breast11 explored treatment in the preoperative setting, evaluating how these agents may enhance pathologic response. In the metastatic setting, DESTINY-Breast09 studied patients with previously untreated HER2-positive metastatic breast cancer to assess the role of antibody-drug conjugates earlier in the disease course. Examining these specific populations is essential because each group faces unique prognostic challenges and therapeutic needs.
